Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anthera says final Phase IIb data back blisibimod despite earlier failure

This article was originally published in Scrip

Executive Summary

Anthera Pharmaceuticals believes the final set of clinical data from the Phase IIb PEARL-SC study with blisibimod in patients with systemic lupus erythematosus add fuel to its argument that despite the trial failing to meet its primary endpoint, the results are sufficient to pursue the product into Phase III.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel